ATE300531T1 - Isonipecotamide zur behandlung von integrin vermittelten störungen - Google Patents

Isonipecotamide zur behandlung von integrin vermittelten störungen

Info

Publication number
ATE300531T1
ATE300531T1 AT00966823T AT00966823T ATE300531T1 AT E300531 T1 ATE300531 T1 AT E300531T1 AT 00966823 T AT00966823 T AT 00966823T AT 00966823 T AT00966823 T AT 00966823T AT E300531 T1 ATE300531 T1 AT E300531T1
Authority
AT
Austria
Prior art keywords
isonipecotamide
integrin
treatment
mediated disorders
mediated
Prior art date
Application number
AT00966823T
Other languages
English (en)
Inventor
Michael J Costanzo
William J Hoekstra
Bruce E Maryanoff
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE300531T1 publication Critical patent/ATE300531T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00966823T 1999-09-29 2000-09-22 Isonipecotamide zur behandlung von integrin vermittelten störungen ATE300531T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15661799P 1999-09-29 1999-09-29
US66713400A 2000-09-21 2000-09-21
PCT/US2000/026163 WO2001023376A1 (en) 1999-09-29 2000-09-22 Isonipecotamides for the treatment of integrin-mediated disorders

Publications (1)

Publication Number Publication Date
ATE300531T1 true ATE300531T1 (de) 2005-08-15

Family

ID=26853350

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00966823T ATE300531T1 (de) 1999-09-29 2000-09-22 Isonipecotamide zur behandlung von integrin vermittelten störungen

Country Status (18)

Country Link
US (1) US7718673B2 (de)
EP (1) EP1133489B9 (de)
CN (1) CN1352641A (de)
AR (1) AR034098A1 (de)
AT (1) ATE300531T1 (de)
AU (1) AU7711000A (de)
BR (1) BR0007183A (de)
CA (1) CA2352957A1 (de)
CZ (1) CZ20011872A3 (de)
DE (2) DE60021521T4 (de)
ES (1) ES2244474T3 (de)
HU (1) HUP0200439A2 (de)
NO (1) NO20012612L (de)
NZ (1) NZ511997A (de)
PL (1) PL347976A1 (de)
RU (1) RU2001114518A (de)
WO (1) WO2001023376A1 (de)
YU (1) YU22802A (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0731088B1 (de) 1990-11-19 2000-10-04 Monsanto Company Inhibitoren retroviraler Proteasen
AU2003267991B2 (en) 2002-07-11 2009-10-08 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
PL1734996T3 (pl) * 2004-04-02 2013-09-30 Univ California Sposoby i kompozycje do leczenia i profilaktyki choroby związanej z integryną alfa v beta 5
AU2009246572A1 (en) 2008-05-16 2009-11-19 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
CA2767409C (en) 2009-07-24 2018-10-30 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
JP2020505333A (ja) * 2017-01-09 2020-02-20 アルデリックス, インコーポレイテッド Nhe媒介性アンチポートの阻害薬

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2830555A1 (de) 1978-07-12 1980-03-06 Bayer Ag Chinazolinonyl-verbindungen
GB8829296D0 (en) 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
JPH04334357A (ja) * 1991-05-02 1992-11-20 Fujirebio Inc 酵素阻害作用を有するアシル誘導体
US5352667A (en) 1991-11-22 1994-10-04 Ofer Lider Non-peptidic surrogates of the Arg-Gly-Asp sequence and pharmaceutical compositions comprising them
DE4208051A1 (de) * 1992-03-13 1993-09-16 Bayer Ag Substituierte phenylessigsaeureamide
WO1994012181A1 (en) 1992-12-01 1994-06-09 Merck & Co., Inc. Fibrinogen receptor antagonists
US6268380B1 (en) 1993-02-19 2001-07-31 G. D. Searle & Co. Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de) * 1993-03-26 1994-09-29 Cassella Ag Neue Harnstoffderivate, ihre Herstellung und Verwendung
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
RU2161155C2 (ru) 1993-09-22 2000-12-27 Фудзисава Фармасьютикал Ко., Лтд Производные n-(3-пиперидинилкарбонил)-бета-аланина в качестве антагонистов фактора активации тромбоцитов (фат), способ получения, фармацевтическая композиция и способ лечения
CA2190870A1 (en) 1994-05-27 1995-12-07 George D. Hartman Compounds for inhibiting osteoclast-mediated bone resorption
BR9510360A (pt) * 1994-12-23 1997-12-23 Thomae Gmbh Dr K Derivados de piperazina medicamentos contendo esses compostos sua aplicação e processo para sua preparação
US5700801A (en) * 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US5602155A (en) * 1995-01-17 1997-02-11 G. D. Searle & Co. Platelet aggregation inhibitors
MX9801228A (es) 1995-08-14 1998-05-31 Scripps Research Inst METODOS Y COMPOSICIONES UTILES PARA LA INHIBICION DE ANGIOGENESIS MEDIADA POR ALFAV beta5.
CZ293323B6 (cs) 1995-08-30 2004-04-14 G. D. Searle & Co. Meta-guanidinové, močovinové, thiomočovinové nebo azacyklické deriváty aminobenzoové kyseliny jako antagonisty integrinů
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
JPH11513382A (ja) * 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング 5員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
DE19548709A1 (de) 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
PT891325E (pt) * 1996-03-29 2002-07-31 Searle & Co Derivados do acido fenilpropanoico para-substituido como antagonistas de integrina
PT923555E (pt) 1996-05-01 2005-09-30 Ortho Mcneil Pharm Inc Derivados carboxamida de pirrolidina, piperidina e hexa-hidroazepina para o tratamento de disturbios tromboticos
DE19642591A1 (de) 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
JP3841898B2 (ja) * 1996-11-21 2006-11-08 三菱電機株式会社 深部線量測定装置
CA2272090A1 (en) 1996-12-09 1998-06-18 Matthew J. Fisher Integrin antagonists
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
WO1999016758A1 (en) 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6066651A (en) 1997-10-29 2000-05-23 Ortho-Mcneil Pharmaceutical, Inc. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders
AU1415099A (en) 1997-11-18 1999-06-07 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
WO1999050249A2 (en) 1998-04-01 1999-10-07 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
DK1077941T3 (da) 1998-05-11 2009-12-07 Novo Nordisk As Forbindelser med væksthormonfrigörende egenskaber
TW591026B (en) * 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
US6388054B1 (en) 1998-08-20 2002-05-14 John M. Stewart Anti-cancer compounds
AU2164300A (en) 1998-12-04 2000-06-26 N.V. Organon Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin
EP1208101A4 (de) 1999-08-06 2003-03-19 Smithkline Beecham Corp Zur behandlung von schlaganfällen nützliche vitronektin-rezeptor-antagonisten
EP1203070A1 (de) 1999-08-10 2002-05-08 The Procter & Gamble Company Nichtwässeriges flüssiges waschmittel mit waschwasserlöslichen wenig dichten füllstoffteilchen

Also Published As

Publication number Publication date
WO2001023376A1 (en) 2001-04-05
CN1352641A (zh) 2002-06-05
DE60021521D1 (de) 2005-09-01
PL347976A1 (en) 2002-05-06
DE60021521T4 (de) 2006-09-21
CA2352957A1 (en) 2001-04-05
ES2244474T3 (es) 2005-12-16
EP1133489B9 (de) 2006-05-03
YU22802A (sh) 2005-06-10
RU2001114518A (ru) 2003-04-20
EP1133489A1 (de) 2001-09-19
NO20012612D0 (no) 2001-05-28
AR034098A1 (es) 2004-02-04
CZ20011872A3 (cs) 2002-03-13
NZ511997A (en) 2004-12-24
EP1133489B1 (de) 2005-07-27
DE60021521T2 (de) 2006-06-08
AU7711000A (en) 2001-04-30
US7718673B2 (en) 2010-05-18
NO20012612L (no) 2001-07-17
US20030181440A1 (en) 2003-09-25
BR0007183A (pt) 2002-02-05
HUP0200439A2 (en) 2002-06-29

Similar Documents

Publication Publication Date Title
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60028358D1 (de) Hmg1 antagonisten zur behandlung von entzündungen
DE60023873D1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
ATE394103T1 (de) Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE50014041D1 (de) Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis
DE60030554T8 (de) Verwendungen von et743 zur behandlung von krebs
DE69925865D1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
ATE279386T1 (de) Retinoide zur behandlung von emphysem
EP1117431A4 (de) Behandlung von acidose
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60104791D1 (de) Cyclobutendion-Derivate zur Behandlung von Artherosclerose
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE60001255D1 (de) Zusammensetzung zur Behandlung von Polyesterfaser
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
DE60021521D1 (de) Isonipecotamide zur behandlung von integrin vermittelten störungen
DE69918541D1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties